Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | EPHB4 | Direct | 3 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | EPHB4 | Direct | 2 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | EPHB4 | Direct | 1 | ||||||||
| bevacizumab, dasatinib, placebo | EPHB4 | Direct | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | EPHB4 | Direct | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | EPHB4 | Direct | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | EPHB4 | Direct | 1 | ||||||||
| dasatinib, mfolfox6 | EPHB4 | Direct | 1 | ||||||||
| dasatinib, pharmacological study | EPHB4 | Direct | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | EPHB4 | Direct | 1 | ||||||||
| tesevatinib | EPHB4 | Direct | 1 | ||||||||
| vandetanib | EPHB4 | Direct | yes | 0 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | NTRK1 | SSL via NTRK1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | NTRK1 | SSL via NTRK1 | 4 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | LCK | SSL via LCK | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | NTRK1 | SSL via NTRK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CB | SSL via PIK3CB | 3 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | LCK | SSL via LCK | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | NTRK1 | SSL via NTRK1 | 2 | ||||||||
| nintedanib | LCK | SSL via LCK | 2 | ||||||||
| nintedanib, pembrolizumab | LCK | SSL via LCK | 2 | ||||||||
| regorafenib | NTRK1 | SSL via NTRK1 | 2 | ||||||||
| regorafenib, laboratory biomarker analysis | NTRK1 | SSL via NTRK1 | 2 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | LCK | SSL via LCK | 1 | ||||||||
| bevacizumab, dasatinib, placebo | LCK | SSL via LCK | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CB | SSL via PIK3CB | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, larotrectinib, magnetic resonance imaging | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CB | SSL via PIK3CB | 1 | ||||||||
| byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, mfolfox6 | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, pharmacological study | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | LCK | SSL via LCK | 1 | ||||||||
| entrectinib | NTRK1 | SSL via NTRK1 | yes | 1 | |||||||
| gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy | NFKB2 | SSL via NFKB2 | 1 | ||||||||
| gemcitabine, oxaliplatin, imatinib | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| imatinib, irinotecan, carboplatin | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| medical cannabis | AANAT | SSL via AANAT | 1 | ||||||||
| nabiximols, temozolomide, nabiximols-matched placebo | AANAT | SSL via AANAT | 1 | ||||||||
| ponatinib | LCK | SSL via LCK | 1 | ||||||||
| regorafenib, lomustine | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| regorafenib, nivolumab, capeox, folfox regimen | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| regorafenib, temozolomide | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| sulfasalazine | NFKB2 | SSL via NFKB2 | 1 | ||||||||
| temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 | NTRK1 | SSL via NTRK1 | 1 | ||||||||
| cenegermin | NTRK1 | SSL via NTRK1 | yes | 0 | |||||||
| dasatinib | LCK | SSL via LCK | yes | 0 | |||||||
| larotrectinib | NTRK1 | SSL via NTRK1 | yes | 0 | |||||||
| larotrectinib sulfate | NTRK1 | SSL via NTRK1 | yes | 0 | |||||||
| midostaurin | PRKCZ | SSL via PRKCZ | yes | 0 | |||||||
| pazopanib | LCK | SSL via LCK | yes | 0 | |||||||
| pazopanib hydrochloride | LCK | SSL via LCK | yes | 0 | |||||||
| vandetanib | LCK | SSL via LCK | yes | 0 |